{"id":"mk0663-etoricoxib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal upset"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This selective inhibition of COX-2 results in reduced inflammation and pain, making it effective for treating conditions such as osteoarthritis and rheumatoid arthritis. Etoricoxib's mechanism of action is distinct from traditional NSAIDs, which inhibit both COX-1 and COX-2 enzymes.","oneSentence":"Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:50.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT07454369","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-10-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT05014490","phase":"PHASE1","title":"Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-02-24","conditions":"Bioequivalence, Healthy Subjects","enrollment":28},{"nctId":"NCT01294696","phase":"","title":"Survey of Osteoarthritis Real World Therapies (MK-0663-140)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-10","conditions":"Osteoarthritis","enrollment":1261},{"nctId":"NCT00092729","phase":"PHASE3","title":"An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-07","conditions":"Dysmenorrhea","enrollment":129},{"nctId":"NCT00140972","phase":"PHASE4","title":"A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-03","conditions":"Osteoarthritis","enrollment":160},{"nctId":"NCT00092703","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-27","conditions":"Osteoarthritis","enrollment":6000},{"nctId":"NCT00380627","phase":"PHASE4","title":"Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Pain","enrollment":337},{"nctId":"NCT00269191","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-05","conditions":"Osteoarthritis","enrollment":528},{"nctId":"NCT00142558","phase":"PHASE4","title":"A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Acute Gout","enrollment":180},{"nctId":"NCT00092768","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT00542087","phase":"PHASE3","title":"Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-03-22","conditions":"Osteoarthritis","enrollment":516},{"nctId":"NCT00092755","phase":"PHASE3","title":"An Investigational Drug in Patients With Osteoarthritis (0663-073)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-09","conditions":"Osteoarthritis","enrollment":548},{"nctId":"NCT00092781","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT01980940","phase":"PHASE1, PHASE2","title":"The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-12-23","conditions":"Osteoarthritis Pain","enrollment":70},{"nctId":"NCT01208207","phase":"PHASE3","title":"A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Spondylitis, Ankylosing","enrollment":1015},{"nctId":"NCT01208181","phase":"PHASE3","title":"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Arthritis, Rheumatoid","enrollment":1404},{"nctId":"NCT01327638","phase":"","title":"Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02-15","conditions":"Spondylarthropathies; Spondylitis, Ankylosing","enrollment":21108},{"nctId":"NCT05256342","phase":"NA","title":"Biomarkers for Prediction of Analgesic Efficacy in Knee OA.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2021-12-30","conditions":"Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy","enrollment":17},{"nctId":"NCT05683574","phase":"PHASE3","title":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-05-30","conditions":"Third Molar Extraction","enrollment":""},{"nctId":"NCT04920019","phase":"NA","title":"Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2020-10-22","conditions":"Hepatoma, Pancreas Cancer","enrollment":140},{"nctId":"NCT05533073","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2020-08-03","conditions":"Healthy","enrollment":42},{"nctId":"NCT05532280","phase":"PHASE1","title":"Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-12-28","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT02503839","phase":"PHASE1","title":"Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic","status":"COMPLETED","sponsor":"Anne Margarita Dyrhol Riise","startDate":"2015-11","conditions":"Tuberculosis","enrollment":39},{"nctId":"NCT00393354","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":325},{"nctId":"NCT00242489","phase":"PHASE2","title":"Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-06","conditions":"Osteoarthritis","enrollment":1167},{"nctId":"NCT00250445","phase":"PHASE3","title":"A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Rheumatoid Arthritis,Osteoarthritis","enrollment":23498},{"nctId":"NCT00393211","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":319},{"nctId":"NCT01685424","phase":"","title":"Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-30","conditions":"Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":79189},{"nctId":"NCT01077843","phase":"","title":"Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-08-17","conditions":"Ankylosing Spondylitis","enrollment":27381},{"nctId":"NCT01429168","phase":"PHASE4","title":"A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2011-10","conditions":"Osteoarthritis","enrollment":""},{"nctId":"NCT00092742","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Rheumatoid Arthritis","enrollment":4086},{"nctId":"NCT00095017","phase":"PHASE2","title":"Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Bone Neoplasms","enrollment":""},{"nctId":"NCT00380523","phase":"PHASE4","title":"Analgesic Treatment Mediated by Arcoxia (0663-093)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Pain","enrollment":237},{"nctId":"NCT00090181","phase":"PHASE4","title":"Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Chronic Low Back Pain","enrollment":401},{"nctId":"NCT01462370","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-11","conditions":"Dysmenorrhea","enrollment":139},{"nctId":"NCT00788710","phase":"PHASE3","title":"A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-10","conditions":"Acute Pain Following a Total Abdominal Hysterectomy","enrollment":430},{"nctId":"NCT00945035","phase":"PHASE1","title":"Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11","conditions":"Pain","enrollment":36},{"nctId":"NCT00694369","phase":"PHASE3","title":"A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Postoperative Dental Pain","enrollment":588},{"nctId":"NCT00757627","phase":"PHASE4","title":"Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12","conditions":"Pain","enrollment":500},{"nctId":"NCT00820027","phase":"PHASE3","title":"Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-12-15","conditions":"Pain, Postoperative","enrollment":776},{"nctId":"NCT01554163","phase":"PHASE3","title":"Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-03","conditions":"Osteoarthritis of the Knee","enrollment":239},{"nctId":"NCT01572675","phase":"","title":"A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-06","conditions":"Osteoarthritis","enrollment":547},{"nctId":"NCT00264147","phase":"PHASE2","title":"Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":761},{"nctId":"NCT01067430","phase":"PHASE4","title":"Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)","status":"WITHDRAWN","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2010-04","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT03117894","phase":"NA","title":"PECS-2 for Breast Surgery","status":"COMPLETED","sponsor":"Umeå University","startDate":"2017-05-23","conditions":"Breast Neoplasm Female, Regional Anesthesia, Anesthesia","enrollment":200},{"nctId":"NCT04830579","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2021-04-10","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT00746720","phase":"PHASE2","title":"Modulation of the Surgical Inflammatory Response by Etoricoxib","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2006-05","conditions":"Pain, Osteoarthritis, Hip, Postoperative Pain","enrollment":23},{"nctId":"NCT03011905","phase":"PHASE3","title":"Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-01","conditions":"Brachial Plexus Block, Pain, Postoperative","enrollment":53},{"nctId":"NCT04144101","phase":"PHASE4","title":"Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2007-03-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03422575","phase":"NA","title":"Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2015-12","conditions":"Healthy","enrollment":26},{"nctId":"NCT02954484","phase":"PHASE3","title":"Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2015-04","conditions":"Pain, Postoperative","enrollment":116},{"nctId":"NCT01300780","phase":"NA","title":"Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching","status":"COMPLETED","sponsor":"Eloisa Andrade de Paula","startDate":"2010-04","conditions":"Color Changes During Tooth Formation","enrollment":30},{"nctId":"NCT01269515","phase":"PHASE2","title":"Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients","status":"COMPLETED","sponsor":"Dag Kvale","startDate":"2010-10","conditions":"HIV","enrollment":60},{"nctId":"NCT00427999","phase":"PHASE2","title":"Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":"Prostate Cancer","enrollment":67},{"nctId":"NCT02884986","phase":"NA","title":"Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2015-01","conditions":"Adverse Anesthesia Outcome","enrollment":60},{"nctId":"NCT02750917","phase":"PHASE3","title":"Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Foisor Orthopedics Clinical Hospital","startDate":"2014-09","conditions":"Postoperative Pain","enrollment":120},{"nctId":"NCT02534610","phase":"NA","title":"Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Foisor Orthopedics Clinical Hospital","startDate":"2014-01","conditions":"Postoperative Pain","enrollment":165},{"nctId":"NCT01091675","phase":"PHASE3","title":"Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs","status":"COMPLETED","sponsor":"Spanish Foundation of Rheumatology","startDate":"2010-09","conditions":"Ankylosing Spondylitis","enrollment":58},{"nctId":"NCT02456363","phase":"PHASE2","title":"Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Chung Shan Medical University","startDate":"2009-11","conditions":"Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT01229774","phase":"PHASE3","title":"Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2011-02","conditions":"Coxarthrosis, Arthroplasties Hip Replacement, Perioperative Blood Loss","enrollment":100},{"nctId":"NCT02149758","phase":"PHASE4","title":"EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).","status":"COMPLETED","sponsor":"Tatyasaheb Kore Dental College","startDate":"2013-01","conditions":"Cyclooxygenase Two Inhibitors, Etoricoxib, Periodontitis","enrollment":40},{"nctId":"NCT01259830","phase":"PHASE4","title":"Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery","status":"TERMINATED","sponsor":"Claudia Spies","startDate":"2011-03","conditions":"Post-operative Pain","enrollment":81},{"nctId":"NCT01022190","phase":"PHASE4","title":"Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-12","conditions":"Ossification, Heterotopic","enrollment":42},{"nctId":"NCT00954785","phase":"PHASE4","title":"Etoricoxib in Acute Ankle Ligament Sprains","status":"WITHDRAWN","sponsor":"University of Cape Town","startDate":"2009-11","conditions":"Sprain","enrollment":""},{"nctId":"NCT01002690","phase":"NA","title":"COX-2 Inhibition in Allergic Asthma","status":"COMPLETED","sponsor":"Barbro Dahlen","startDate":"2009-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT01088256","phase":"PHASE2","title":"Efficacy of Etoricoxib on Peripheral Hyperalgesia","status":"TERMINATED","sponsor":"Ruhr University of Bochum","startDate":"2011-02","conditions":"Causalgia, Polyneuropathy, Postherpetic Neuralgia","enrollment":9},{"nctId":"NCT00755521","phase":"PHASE4","title":"Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-09","conditions":"Fibromyalgia","enrollment":80},{"nctId":"NCT01614301","phase":"PHASE1, PHASE2","title":"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma","status":"UNKNOWN","sponsor":"University of Regensburg","startDate":"2012-05","conditions":"Advanced Melanoma","enrollment":136},{"nctId":"NCT00927004","phase":"PHASE4","title":"Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Curtin University","startDate":"2010-08","conditions":"Osteoarthritis, Pain","enrollment":80},{"nctId":"NCT01361789","phase":"PHASE4","title":"COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2004-01","conditions":"Rupture of Anterior Cruciate Ligament","enrollment":93},{"nctId":"NCT01264237","phase":"PHASE4","title":"Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain","status":"UNKNOWN","sponsor":"Analgesic Solutions","startDate":"2011-03","conditions":"Postherpetic Neuralgia, Neuralgia","enrollment":120},{"nctId":"NCT01148303","phase":"PHASE4","title":"Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2010-07","conditions":"Headache, Fasting, Fasting Headache","enrollment":220},{"nctId":"NCT00554346","phase":"PHASE4","title":"A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-05","conditions":"Post-operational Pain","enrollment":64},{"nctId":"NCT00733421","phase":"PHASE4","title":"The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2008-10","conditions":"Postoperative Pain","enrollment":100},{"nctId":"NCT00440739","phase":"PHASE4","title":"Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2005-09","conditions":"Pain","enrollment":128},{"nctId":"NCT00565682","phase":"PHASE4","title":"Pain Post Abdominal Laparoscopy Prevention With Arcoxia","status":"COMPLETED","sponsor":"Hospital Vozandez","startDate":"2006-04","conditions":"Laparoscopic Surgery for Appendicitis, Laparoscopic Surgery for Cholecystitis, Laparoscopic Surgery for Ovarian Cysts","enrollment":60},{"nctId":"NCT00529594","phase":"NA","title":"Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-08","conditions":"Proliferative Diabetic Retinopathy","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":942,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0663, etoricoxib","genericName":"MK0663, etoricoxib","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation. Used for Osteoarthritis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}